Home Newsfeeds NexImmune Q2 EPS $(0.69) Down From $(0.54) YoY

NexImmune Q2 EPS $(0.69) Down From $(0.54) YoY

NexImmune (NASDAQ:NEXI) reported quarterly losses of $(0.69) per share. This is a 27.78 percent decrease over losses of $(0.54) per share from the same period last year.

byBenzinga Newsdesk

August 15, 2022

1 minute read

NexImmune (NASDAQ:NEXI) reported quarterly losses of $(0.69) per share. This is a 27.78 percent decrease over losses of $(0.54) per share from the same period last year.

Biodexa’s MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers; Shares Spike Higher

By Benzinga Newsdesk

March 28, 8:19 AM

Topline Results For Progression-Free Survival Expected In Q2 2024CARDIFF, UK / ACCESSWIRE / March 28, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) ("Biodexa"), an acquisition-focused biopharmaceutical company, is

BDRX

Why Ball Shares Are Shooting Higher Today

By Lekha Gupta

August 17, 5:40 AM

Ball Corp (NYSE: BALL) shares are trading higher by around 5% after the company disclosed a

BALL

Citigroup Maintains Neutral on Squarespace, Raises Price Target to $30

By Benzinga Newsdesk

March 8, 7:14 AM

Citigroup analyst Ygal Arounian maintains Squarespace (NYSE:SQSP) with a Neutral and raises the price target from $21 to $30.

SQSP

CBD To Extend Shelf-Life Of Fresh Produce? This Company Is Working On It

By Vuk Zdinjak

July 25, 10:59 AM

Pressure BioSciences, Inc. (OTCQB: PBIO) announced today the initiation of studies to evaluate and demonstrate its industrially-scalable UltraShear Technology platform for producing oil-in-water nanoemulsions in the preparation of edible coatings of Nano-CBD

PBIO

NexImmune Q2 EPS $(0.69) Down From $(0.54) YoY

Related Posts

Biodexa’s MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers; Shares Spike Higher

Why Ball Shares Are Shooting Higher Today

Citigroup Maintains Neutral on Squarespace, Raises Price Target to $30

CBD To Extend Shelf-Life Of Fresh Produce? This Company Is Working On It